Annual report pursuant to Section 13 and 15(d)

SELECTED QUARTERLY FINANCIAL DATA (Tables)

v3.10.0.1
SELECTED QUARTERLY FINANCIAL DATA (Tables)
12 Months Ended
Dec. 31, 2018
SELECTED QUARTERLY FINANCIAL DATA  
Schedule of selected quarterly financial data

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Year Ended December 31, 2018

 

Year Ended December 31, 2017

 

 

 

Q1

 

Q2

 

Q3

 

Q4

 

Q1

 

Q2

 

Q3

 

Q4

 

 

 

(unaudited, in thousands, except per share amounts)

 

Revenue

    

$

 —

    

$

1,787

    

$

4,865

    

$

37,857

    

$

3,584

    

$

 —

    

$

900

    

$

 —

 

Gross profit*

    

$

 —

 

$

1,757

 

$

4,796

 

$

7,107

 

$

 —

 

$

 —

 

$

 —

 

$

 —

 

Net loss

 

$

(24,385)

 

$

(25,557)

 

$

(23,766)

 

$

3,228

 

$

(15,314)

 

$

(19,147)

 

$

(17,660)

 

$

(25,871)

 

Net income (loss) per share, basic and diluted:

 

$

(0.17)

 

$

(0.16)

 

$

(0.14)

 

$

0.02

 

$

(0.13)

 

$

(0.16)

 

$

(0.14)

 

$

(0.18)

 

Weighted average shares used in computing net income (loss) per share:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic

 

 

147,114

 

 

161,577

 

 

166,464

 

 

166,680

 

 

113,598

 

 

122,500

 

 

124,628

 

 

144,252

 

Diluted

 

 

147,114

 

 

161,577

 

 

166,464

 

 

167,617

 

 

113,598

 

 

122,500

 

 

124,628

 

 

144,252

 


*Gross profit is computed as Net product sales less Cost of product sales. Prior to the FDA approval, manufacturing and related costs were charged to research and development expense. Therefore, these costs were not capitalized and as a result, are not fully reflected in the costs of sales during the periods disclosed above.